Capecitabine/irinotecan or capecitabine/oxaliplatinin combination with bevacizumab is effective andsafe as first-line therapy for metastatic colorectalcancer: A randomized phase II study of the AIOcolorectal study group

Annals of Oncology

Volumn 24, Issue 6, 2013, Pages 1580-1587

  Schmiegel, W ^a,b   Reinacher Schick, A ^c   Arnold, D ^d   Kubicka, S ^e   Freier, W ^f   Dietrich, G ^g   Geissler M ^h   Hegewisch Becker, S ⁱ   Tannapfel, A ^b   Pohl, M ^a   Hinke, A ^j   Schmoll, H J ^k   Graeven, U ^l  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c ST JOSEF HOSPITAL   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

^e District Hospital Reutlingen   (Germany)

^f Center of Oncology   (Germany)

^g Hospital Bietigheim Bissingen   (Germany)

^h Gastroenterology and Internal Medicine   (Germany)

ⁱ UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^j WiSP GmbH   (Germany)

^k University Clinic Halle (Saale)   (Germany)

^l Krankenhaus Maria Hilf Daun   (Germany)

more..

Author keywords

Bevacizumab; CAPIRI; CAPOX; KRAS; Metastastic colorectal cancer

Indexed keywords

BEVACIZUMAB; CAPECITABINE; IRINOTECAN; OXALIPLATIN;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CATHETER THROMBOSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EMBOLISM; FEMALE; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; ILEUS; INTENTION TO TREAT ANALYSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT DURATION; VOMITING;

EID: 84878468561     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt028     Document Type: Article

References (31)

1. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
2. Saltz LB, Clarke S, Díaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 2008; 26: 2013-2019. Erratum in: J Clin Oncol 2008; 26: 3110
3. Van Cutsem E, Hoff PM, Harper P et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: Integrated efficacy data and novel analyses from two large, randomized, phase III trials. Br J Cancer 2004; 90: 1190-1197.
4. Twelves C, Wong A, Nowacki MP et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352: 2696-2704.
5. Arkenau HT, Arnold D, Cassidy J et al. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. J Clin Oncol 2008; 26: 5910-5917.
6. Cassidy J, Clarke S, Diaz-Rubio E et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008; 26: 2006-2012.
7. Koopman M, Antonini NF, Douma J et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007; 370: 135-142.
8. Fuchs CS, Marshall J, Mitchell E et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007; 25: 4779-4786.
9. Köhne CH, De Greve J, Hartmann JT et al. Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. Ann Oncol 2008; 19: 920-926.
10. Grothey A, Jordan K, Kellner O et al. Capecitabine/ irinotecan (CapIri) and capecitabine/oxaliplatin (CapOx) are active second-line protocols in patients with advanced colorectal cancer (ACRC) after failure of first-line combination therapy: results of a randomized phase II study. J Clin Oncol 2004; 22: 14s (suppl; abstr 3534).
11. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
12. Köhne CH, Cunningham D, Di CF et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: Results of a multivariate analysis of 3825 patients. Ann Oncol 2002; 13: 308-317.
13. Delord JP, Pierga JY, Dieras V et al. A phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours. Br J Cancer 2005; 92: 820-826.
14. Rea DW, Nortier JW, Ten Bokkel Huinink WW et al. A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. Ann Oncol 2005; 16: 1123-1132.
15. Schmiegel WH, Reinacher-Schick A, Freier W et al. Comparable safety and response rate with bevacizumab in combination with capecitabine/oxaliplatin (CapOx/Bev) versus capecitabine/irinotecan (CapIri/Bev) in advanced CRC (mCRC): a randomized phase II study of the AIO GI tumor study group. J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 4034.
16. Haller DG, Cassidy J, Clarke SJ et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 2008; 26: 2118-2123.
17. Moosmann N, Fischer von Weikersthal L, Vehling-Kaiser U et al. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104-a randomized trial of the german AIO CRC group. J Clin Oncol 2011; 29: 1050-1055.
18. Hecht JR, Mitchell E, Chidiac T et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009; 27(5): 672-680.
19. Van Cutsem E, Rivera F, Berry S et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009; 20: 1842-1847.
20. Kozloff M, Yood MU, Berlin J et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 2009; 14: 862-870.
21. Arnold D, Kindler M, Petersen V et al. Bevacizumab plus chemotherapy as first-line treatment for patients with metastatic colorectal cancer: First results from a large community-based observational cohort study in Germany. Presented at 2010 ASCO Gastrointestinal Cancers Symposium (abstr 439).
22. Bendell JC, Bekaii-Saab TS, Cohn AL et al. Similarities in treatment (Tx) patterns and clinical outcomes (CO) in patients ( pts) with metastatic colorectal cancer (mCRC) initially treated with FOLFOX/BV or FOLFIRI/BV: Results from ARIES, a bevacizumab (BV) observational study. J Clin Oncol 2011; 29: (suppl 4; abstr 480).
23. Tol J, Koopman M, Cats A et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009; 360: 563-572.
24. Díaz-Rubio E, Gómez-España A, Massutí B et al. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist 2012; 17(1): 15-25.
25. Ducreux M, Adenis A, Pignon JP et al. Efficacy and safety of bevacizumab-based combination regimens in patients with metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab + FOLFIRI vs. bevacizumab + XELIRI (FNCLCC ACCORD 13/0503 study). Eur J Cancer 2009; (Suppl 7):347 (abstr 6084).
26. O'Connell MJ, Campbell ME, Goldberg RM et al. Survival following recurrence in stage II and III colon cancer: Findings from the ACCENT data set. J Clin Oncol 2008; 26: 336-31.
27. Richman SD, Seymour MT, Chambers P et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009; 27(35): 5931-5937.
28. Maughan TS, Adams RA, Smith CG et al. Addition of cetuximab to oxaliplatinbased first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011; 377 (9783): 2103-2114.
29. Ocvirk J, Brodowicz T, Wrba F et al. Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. World J Gastroenterol 2010; 16(25): 3133-3143.
30. Douillard JY, Siena S, Cassidy J et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28(31): 4697-4705.
31. Meyerhardt JA, Li L, Sanoff HK et al. Effectiveness of bevacizumab with first-line combination chemotherapy for medicare patients with stage IV colorectal cancer. J Clin Oncol 2012; 30(6): 608-615.